NKE vs. AYTU
NKE (NIKE, Inc.) and AYTU (Aytu BioPharma, Inc.) are both stocks. NKE operates in Footwear & Accessories (Consumer Cyclical), while AYTU operates in Drug Manufacturers - Specialty & Generic (Healthcare). Over the past 5 years, NKE returned -18.65%/yr vs -53.73%/yr for AYTU. At a 0.10 correlation, their price movements are largely independent.
Performance
NKE vs. AYTU - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NKE achieves a -31.08% return, which is significantly lower than AYTU's -11.92% return.
NKE
- 1D
- 0.58%
- 1M
- -1.19%
- YTD
- -31.08%
- 6M
- -30.90%
- 1Y
- -29.27%
- 3Y*
- -24.25%
- 5Y*
- -18.65%
- 10Y*
- -1.05%
AYTU
- 1D
- 1.78%
- 1M
- -8.40%
- YTD
- -11.92%
- 6M
- 2.23%
- 1Y
- 14.50%
- 3Y*
- 12.70%
- 5Y*
- -53.73%
- 10Y*
- —
NKE vs. AYTU - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NKE NIKE, Inc. | -31.08% | -13.83% | -29.11% | -6.01% | -29.04% | 18.70% | 40.97% | 38.09% | 19.87% | 19.55% |
AYTU Aytu BioPharma, Inc. | -11.92% | 52.94% | -40.14% | -24.87% | -86.00% | -77.42% | -38.35% | 22.41% | -98.22% | -88.85% |
Correlation
The correlation between NKE and AYTU is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.06 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Feb 2, 2017 | 0.10 |
Fundamentals
NKE:
$64.00B
AYTU:
$24.07M
NKE:
$1.52
AYTU:
-$2.91
NKE:
1.38
AYTU:
0.47
NKE:
4.54
AYTU:
0.68
NKE:
$46.52B
AYTU:
$56.60M
NKE:
$18.99B
AYTU:
$36.14M
NKE:
$3.33B
AYTU:
-$27.34M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NKE vs. AYTU — Risk / Return Rank
NKE
AYTU
NKE vs. AYTU - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for NIKE, Inc. (NKE) and Aytu BioPharma, Inc. (AYTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NKE | AYTU | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.04 | ||
| Sortino ratioReturn per unit of downside risk | -1.74 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.10 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.64 | 0.41 | -1.05 |
| Martin ratioReturn relative to average drawdown | -1.23 | 0.97 | -2.21 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NKE | AYTU | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.77 | 0.27 | -1.04 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.52 | -0.63 | +0.11 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.03 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.41 | -0.36 | +0.77 |
Drawdowns
NKE vs. AYTU - Drawdown Comparison
The maximum NKE drawdown since its inception was -75.19%, smaller than the maximum AYTU drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for NKE and AYTU.
Loading charts...
Drawdown Indicators
| NKE | AYTU | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.19% | -100.00% | +24.81% |
Max Drawdown (1Y)Largest decline over 1 year | -46.18% | -35.47% | -10.71% |
Max Drawdown (3Y)Largest decline over 3 years | -64.21% | -70.24% | +6.03% |
Max Drawdown (5Y)Largest decline over 5 years | -74.64% | -99.12% | +24.48% |
Max Drawdown (10Y)Largest decline over 10 years | -74.64% | — | — |
Current DrawdownCurrent decline from peak | -73.59% | -100.00% | +26.41% |
Average DrawdownAverage peak-to-trough decline | -20.91% | -95.15% | +74.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.82% | 14.92% | +8.90% |
Volatility
NKE vs. AYTU - Volatility Comparison
The current volatility for NIKE, Inc. (NKE) is 9.43%, while Aytu BioPharma, Inc. (AYTU) has a volatility of 14.09%. This indicates that NKE experiences smaller price fluctuations and is considered to be less risky than AYTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NKE | AYTU | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.43% | 14.09% | -4.66% |
Volatility (6M)Calculated over the trailing 6-month period | 29.22% | 33.39% | -4.17% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.22% | 55.06% | -16.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 35.82% | 85.66% | -49.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.25% | 188.20% | -155.95% |
Dividends
NKE vs. AYTU - Dividend Comparison
NKE's dividend yield for the trailing twelve months is around 3.77%, while AYTU has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
AYTU Aytu BioPharma, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NKE NIKE, Inc. | 3.77% | 2.53% | 2.00% | 1.28% | 1.07% | 0.68% | 0.71% | 0.89% | 1.11% | 1.18% | 1.30% | 0.93% |
Financials
NKE vs. AYTU - Financials Comparison
This section allows you to compare key financial metrics between NIKE, Inc. and Aytu BioPharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NKE vs. AYTU - Profitability Comparison
NKE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported a gross profit of 4.53B and revenue of 11.28B. Therefore, the gross margin over that period was 40.2%.
AYTU - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a gross profit of 7.60M and revenue of 12.41M. Therefore, the gross margin over that period was 61.2%.
NKE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported an operating income of 553.00M and revenue of 11.28B, resulting in an operating margin of 4.9%.
AYTU - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported an operating income of -4.06M and revenue of 12.41M, resulting in an operating margin of -32.8%.
NKE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, NIKE, Inc. reported a net income of 520.00M and revenue of 11.28B, resulting in a net margin of 4.6%.
AYTU - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Aytu BioPharma, Inc. reported a net income of -5.62M and revenue of 12.41M, resulting in a net margin of -45.3%.
Frequently Asked Questions
NKE and AYTU have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AYTU has higher volatility (14.09%) compared to NKE (9.43%). In terms of maximum drawdown, NKE dropped -75.19% vs AYTU's -100.00%.
AYTU currently has the higher Sharpe Ratio (0.27 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NKE and AYTU
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer